Session » Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0674

A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial

8:30AM-10:30AM: Abstract Number: 0667

Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk

8:30AM-10:30AM: Abstract Number: 0681

Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes

8:30AM-10:30AM: Abstract Number: 0679

Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout

8:30AM-10:30AM: Abstract Number: 0671

Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices

8:30AM-10:30AM: Abstract Number: 0676

Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert

8:30AM-10:30AM: Abstract Number: 0663

Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout

8:30AM-10:30AM: Abstract Number: 0672

Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years

8:30AM-10:30AM: Abstract Number: 0669

Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review

8:30AM-10:30AM: Abstract Number: 0661

Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial

8:30AM-10:30AM: Abstract Number: 0682

Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey

8:30AM-10:30AM: Abstract Number: 0680

Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions

8:30AM-10:30AM: Abstract Number: 0670

Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone

8:30AM-10:30AM: Abstract Number: 0660

Improving the Gout Flare Chart Review Using Linked Claims-EHR Data

8:30AM-10:30AM: Abstract Number: 0678

Is There a Difference in Self-reported Flare Frequency Between Men and Women?

8:30AM-10:30AM: Abstract Number: 0668

Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence

8:30AM-10:30AM: Abstract Number: 0665

Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study

8:30AM-10:30AM: Abstract Number: 0677

Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women

8:30AM-10:30AM: Abstract Number: 0666

Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic

8:30AM-10:30AM: Abstract Number: 0662

Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials

8:30AM-10:30AM: Abstract Number: 0673

The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study

8:30AM-10:30AM: Abstract Number: 0675

Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial

8:30AM-10:30AM: Abstract Number: 0664

Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].